Clinical studies have shown that high expression of acidosis-related markers in tumors is linked to poor prognosis, underscoring tumor acidity as an appealing target for diagnostic and therapeutic strategies.1,15,21,22 In this study, trajectory analysis via single-cell genomic data from CRC patients revealed that tumor acidosis, dysadherin expression, and CRC progression are closely linked, collectively contributing to cancer progression (Fig. 1b). This evidence concerns the gene FXYD5 and cancer.